PharmaFocus Today – Page 20 – media

Ascletis Investors surges fourfold! A quiet turnaround for Ascletis!

Recently, Ascletis Pharma released Phase II study data for its oral small molecule GLP-1 drug ASC30. In 125 obese or overweight subjects, the 60 mg dose group experienced a weight loss of up to 7.7%, and no weight loss plateau was observed. Following the announcement, Ascletis Pharma’s stock price surged by more than 20% intraday on December 9. In fact, Ascletis Pharma’s stock price has increased approximately fourfold this year, ranking among the top performers in the pharmaceutical industry. 01 The data is amazing. small molecule GLP-1R completely biased agonist developed by Ascletis Pharma . According to publicly available information from Ascletis Pharma, this drug possesses unique and differentiated properties, and can be taken orally once daily or subcutaneously once monthly to quarterly as a treatment or maintenance therapy for long-term weight management. Furthermore, it is not subject to dietary restrictions and can be taken at any time of day. ...
- Source: drugdu
- 66
- December 16, 2025
Fosun Pharma Receives Regulatory Inquiry Letter from SSE Over Planned Controlling Stake Acquisition of Green Valley Pharmaceutical

On December 16, the Shanghai Stock Exchange (SSE) issued a regulatory inquiry letter to Fosun Pharma regarding its external investment in Green Valley Pharmaceutical, addressing matters related to the listed company. On December 15, Fosun Pharma announced that its controlling subsidiary, Fosun Pharma Industrial, had entered into a relevant investment agreement with Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. (“Green Valley Pharmaceutical”) and its existing shareholders. The agreement involves an investment of approximately RMB 1.412 billion to acquire a controlling stake in Green Valley Pharmaceutical. Upon completion of the acquisition, Green Valley Pharmaceutical will become a controlling subsidiary of Fosun Pharma, and its core drug, Sodium Oligomannate Capsules, will be integrated into Fosun Pharma’s innovative drug pipeline. The drug is primarily indicated for the treatment of mild to moderate Alzheimer’s disease. Reference: https://finance.eastmoney.com/a/202512163592385827.html
- Source: drugdu
- 64
- December 16, 2025
Innovation-Driven Vaccine Upgrades, Focusing on Core Products and Pipeline Development

After fifteen years of deep cultivation in the vaccine field, AB&B Bio Tech has accelerated on the path of differentiated innovation. Listed on the Hong Kong Stock Exchange in August, AB&B Bio Tech has fortified its competitive edge with core products such as its first quadrivalent subunit influenza vaccine covering all age groups from 6 months and above. Its Hong Kong IPO was oversubscribed by over 4,000 times. In a recent exclusive interview with China Securities Journal, An Youcai, Chairman and General Manager of AB&B Bio Tech, comprehensively detailed the company’s product strategy, performance delivery logic, use of raised funds, and future development blueprint. He clarified that with “innovation-driven” as the core, the company aims to achieve a revenue target of RMB 2 billion by 2030 through capacity expansion and international布局, striving to join the top tier of domestic vaccine enterprises. Differentiated Strategy Enhances Product Competitiveness AB&B Bio Tech listed ...
- Source: drugdu
- 61
- December 16, 2025
Huadong Medicine has made a significant leap in international research and development. Its new product has been granted orphan drug status by the FDA

On December 15th, Huadong Medicinel (000963) announced that its independently developed ADC innovative drug, Injection HDM2012, has obtained orphan drug qualification recognition (Orphan Drug Designation, ODD) from the US Food and Drug Administration (referred to as “US FDA”) for two indications: gastric cancer and gastroesophageal junction cancer, as well as pancreatic cancer. This proves that the innovative nature of its ADC research has been internationally recognized. Meanwhile, the innovative multi-peptide-based long-acting agonist HDM1005 injection for dual-targeting human GLP-1 (glucagon-like peptide-1) receptor and GIP receptor (glucose-dependent insulinotropic polypeptide), developed by the wholly-owned subsidiary Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (hereinafter referred to as “Zhongmei Huadong”), achieved positive results in the Phase II clinical trial for weight management indications in China. These two milestones signify a significant leap forward for Huadong Pharmaceutical in the internationalization and cutting-edge exploration of new drug research. They not only demonstrate the company’s successful implementation of its ...
- Source: drugdu
- 75
- December 16, 2025
Rona Therapeutics Completes First Cohort Dosing in First-in-Human Phase 1 Clinical Trial of Obesity Treatment RN3161

Rona Therapeutics announced on December 15, 2025, that Cohort 1 dosing for their RN3161 drug, a GalNAc-conjugated siRNA targeting INHBE for obesity, had been completed in its Phase 1 clinical trial. Initial data from this cohort indicated good safety and tolerability, reaching a clinical milestone for the company’s INHBE program. Completion of dosing for the remaining cohorts is expected in 2026. https://finance.eastmoney.com/a/202512153592095373.html
- Source: drugdu
- 57
- December 16, 2025
Juncell Bio plans to list in Hong Kong.

On December 10, Shanghai Junsai Biotechnology Co., Ltd. (hereinafter referred to as “Junsai Biotechnology”) submitted a listing application to the Hong Kong Stock Exchange. According to its prospectus, Junsai Bio is a biotechnology company dedicated to the development of innovative cell therapies and drugs for solid tumors. Its core product, GC101, is expected to become the first approved tumor-infiltrating lymphocyte (TIL) therapy. In 2023, 2024, and the first half of 2025, the company projected net losses of RMB 94 million, RMB 164 million, and RMB 98 million, respectively. The core product GC101 undergoes important testing. According to its prospectus, Junsai Bio focuses on the huge unmet clinical needs in the treatment of solid tumors and is developing the next generation of pan-solid tumor immunotherapy. According to the company, its core product GC101 is currently undergoing a pivotal Phase II clinical trial for the treatment of melanoma, with a Biologics License ...
- Source: drugdu
- 95
- December 15, 2025
Plans to acquire the “Multiple Trace Element Injection Assets” of Tibet Future and its two wholly-owned subsidiaries

On December 14, Zhejiang Zouli Pharmaceutical Co., Ltd. issued an announcement stating that its board of directors had approved the “Proposal on Purchasing an Asset Group and Signing an Acquisition Agreement.” The company plans to acquire a group of trace element injections held by Tibet Future Biomedical Co., Ltd. and its two wholly-owned subsidiaries for a total price (including tax) of RMB 356 million. This asset group covers core assets such as R&D and production technology data, marketing authorizations, trademarks, and patents related to the marketed “Multiple Trace Element Injection (I)” and “Multiple Trace Element Injection (II),” as well as the research and development “Multiple Trace Element Injection (III)” under development. The announcement indicates that multi-trace element injections are a major source of trace elements in parenteral nutrition, especially suitable for nutritional supplementation in special populations such as children and critically ill patients. Among them, multi-trace element injection (I) and ...
- Source: drugdu
- 91
- December 15, 2025
CGE Advances Development of Hexavalent Norovirus Vaccine, Targeting 10-Billion-Yuan Market

News Report – On December 13, the Phase II clinical trial initiation meeting for the hexavalent recombinant norovirus vaccine (a Class 1.1 new drug) independently developed by Vazyme Life Sciences Co., Ltd. (hereinafter referred to as “Vazyme”), a subsidiary of Grand Life Science Group Co., Ltd. (referred to as “Grand Life Science”), was successfully held at the Cenxi City Center for Disease Control and Prevention in Guangxi. According to the reporter, this vaccine is currently the fastest progressing hexavalent norovirus vaccine in global clinical development. It utilizes virus-like particle (VLP) technology and covers six globally prevalent genotypes, theoretically providing coverage for over 90% of circulating norovirus strains worldwide. Norovirus is a leading cause of acute gastroenteritis, characterized by rapid mutation, high infectivity, and fast transmission. The period from October to March each year marks the peak season for norovirus infection in China. At present, there are no specific antiviral drugs ...
- Source: drugdu
- 88
- December 15, 2025
JS212 Clinical Trial Application Approved by US FDA for the Treatment of Advanced Solid Tumors

Junshi Biosciences (688180.SH): JS212 Clinical Trial Application for Advanced Solid Tumors Approved by US FDA BEIJING, December 14 – Junshi Biosciences (688180.SH) announced late evening on December 14 that the company recently received notification from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug (IND) application for JS212, an EGFR/HER3 bispecific antibody-drug conjugate (ADC), has been approved for the treatment of advanced solid tumors. According to the announcement, JS212 is a recombinant humanized bispecific ADC targeting the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). It is primarily intended for the treatment of advanced malignant solid tumors. The company stated that the drug can bind to EGFR or HER3 to exert tumor-inhibiting effects, is expected to be effective against a broader range of tumors such as lung cancer and colorectal cancer, and may potentially overcome drug resistance issues. Preclinical studies showed that ...
- Source: drugdu
- 71
- December 15, 2025
China’s first self-developed, new generation solid tumor drug Zoleretinib approved

InnoCare Announces NMPA Approval of China’s First Self-Developed New Generation TRK Inhibitor, Zoleretinib (ICP-723), for NTRK Fusion-Positive Solid Tumors December 11, 2024 – InnoCare Pharma (stock code: 09969.HK, 688428.SH) announced late evening on December 11 that the National Medical Products Administration (NMPA) has approved its self-developed, new-generation TRK inhibitor, Ichinoclax (Zoleretinib, ICP-723). The drug is indicated for the treatment of adult and adolescent patients aged 12 years and older with locally advanced or metastatic solid tumors that harbor a neurotrophic tyrosine receptor kinase (NTRK) gene fusion. This marks Zoleretinib as the first self-developed new-generation TRK inhibitor in China [1]. NTRK gene fusions are found in a variety of tumor types, having been identified in over 26 different solid tumors to date. In China, an estimated 6,500 new cases of NTRK fusion-positive tumors occur annually. These patients typically face short survival periods, rapid disease progression, and high disability rates. Due to ...
- Source: drugdu
- 176
- December 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.